Get Live Data

focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

  2. Share Prices
  3. Glaxosmithkline Share Price
  4. Glaxosmithkline Share News
  5. BROKER RATINGS SUMMARY: UBS Cuts GlaxoSmithKline To Neutral From Buy

Pin to quick picksGlaxosmithkline Share News (GSK)

Glaxosmithkline Information

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,756.00
Bid: 1,753.00
Ask: 1,754.00
Change: -19.00 (-1.07%)
Spread: 1.00 (0.057%)
Open: 1,770.00
High: 1,770.00
Low: 1,740.00
Prev. Close: 1,775.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BROKER RATINGS SUMMARY: UBS Cuts GlaxoSmithKline To Neutral From Buy

Thu, 14th May 2015 08:38

LONDON (Alliance News) - The following shares received analyst recommendations Thursday morning and Wednesday afternoon:
----------
FTSE 100
----------
UBS CUTS GLAXOSMITHKLINE TO 'NEUTRAL' ('BUY') - PRICE TARGET 1500 (1700) PENCE
----------
NUMIS CUTS EASYJET TO 'ADD' ('BUY') - TARGET 1850 (2100) PENCE
----------
NUMIS RAISES JOHNSON MATTHEY PRICE TARGET TO 3780 (3642) PENCE - 'ADD'
----------
TRADERS: JEFFERIES INITIATES CENTRICA WITH 'BUY'
----------
BERNSTEIN CUTS AB FOODS PRICE TARGET TO 2800 (3000) PENCE - 'MARKET-PERFORM'
----------
NOMURA RAISES SABMILLER PRICE TARGET TO 3600 (3400) PENCE - 'NEUTRAL'
----------
DEUTSCHE BANK RAISES MONDI PLC PRICE TARGET TO 1640 (1510) PENCE - 'BUY'
----------
LIBERUM RAISES BARRATT DEVELOPMENTS PRICE TARGET TO 536 (519) PENCE - 'HOLD'
----------
Numis Cuts ITV To Add From Buy, Price Target Raised To 290p From 275p
----------
FTSE 250
----------
NUMIS RAISES ZOOPLA PROPERTY PRICE TARGET TO 245 (215) PENCE - 'ADD'
----------
JPMORGAN CUTS JOHN WOOD PRICE TARGET TO 497 (505) PENCE - 'UNDERWEIGHT'
----------
UBS RAISES PARAGON GROUP PRICE TARGET TO 512 (450) PENCE - 'BUY'
----------
BERENBERG RAISES HOWDEN JOINERY GROUP PRICE TARGET TO 530 (525) PENCE - 'BUY'
----------
MAIN MARKET AND AIM
----------
NUMIS CUTS CHIME COMMUNICATIONS TO 'ADD' ('BUY') - TARGET 339 (400) PENCE
----------
NUMIS RAISES CENTAUR MEDIA PRICE TARGET TO 90 (84) PENCE - 'BUY'
----------
UBS CUTS OXFORD INSTRUMENTS TO 'NEUTRAL' ('BUY') - TARGET 1150 (950) PENCE
----------
Liberum Raises NewRiver Retail Price Target To 355p From 336p, Reiterates Buy
----------
Cantor Fitzgerald Upgrades Greenko Group To Buy From Hold, Price Target Cut To 82p From 86p
----------
PANMURE INITIATES XP POWER WITH 'BUY' - TARGET 1709 PENCE
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
29 Dec 2023 13:01

LONDON MARKET CLOSE: UK equities outclassed by other markets in 2023

(Alliance News) - Stock prices in London closed mixed on Friday, the final trading day of 2023, as the annual returns from UK equities were outshone by international markets.

Read more
20 Dec 2023 13:29

GSK buys rights to Hansoh Pharma antibody-drug conjugate

(Sharecast News) - GSK has agreed to buy the rights to an antibody-drug conjugate (ADC) - HS-20093 - from Chinese biopharmaceutical group Hansoh Pharma.

Read more
19 Dec 2023 15:36

German court quashes CureVac patent after challenge by BioNTech

CureVac shares drop 40%Dispute over intellectual property with BioNTech to continue

*

Read more
18 Dec 2023 17:21

Energy stocks lift UK's FTSE 100, Vodafone shines

Vodafone jumps as Iliad offers to merge Italian units

*

Read more
18 Dec 2023 10:07

GSK's dostarlimab trial in endometrial cancer meets primary endpoint

(Alliance News) - GSK PLC on Monday said a trial of dostarlimab in combination with niraparib for treating endometrial cancer has met its primary endpoint.

Read more
18 Dec 2023 07:55

LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000

(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.

Read more
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
67891011121314

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.